The mechanism of action of furmonertinib was characterized through ATPase assays, revealing its interaction with ABCB1 and ABCG2,suggesting a potential strategy to overcome resistance in EGFR exon 20ins-mutated cancers. Here, ABCB1 is linked to cancer.